Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crofelemer in Short Bowel Syndrome and Intestinal Failure (SBS-IF)
NCT06904872Phase 2Recruiting
- Sponsor
- Napo Therapeutics
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of crofelemer in short bowel syndrome (SBS), intestinal failure (IF), sponsored by Napo Therapeutics. Started May 2025; status: recruiting.
02
Drugs
crofelemer
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on NCT06904872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904872.